Advertisement

Topics

AVEO Announces TIVO-3 Passes The First Safety Monitoring Committee Safety Review

07:00 EST 23 Feb 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
AVEO Oncology (NASDAQ:AVEO) today announced that its pivotal, Phase 3 TIVO-3 trial, a randomized, controlled, multi-center, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carci...

Other Sources for this Article

Argot Partners
David Pitts, 212-600-1902
aveo@argotpartners.com

NEXT ARTICLE

More From BioPortfolio on "AVEO Announces TIVO-3 Passes The First Safety Monitoring Committee Safety Review"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Renal Cell Carcinoma
Renal cell cancer (renal adenocarcinoma or hypernephroma) is the most common type of kidney cancer in adults. More than 8 in every 10 (80%) kidney cancers diagnosed in the UK are this type.  In renal cell cancer the cancerous cells start in the lini...